Search Results - "Brown, Dennis M"

Abstract 2157: Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: Impact of p53 and platinum-resistance by Steino, Anne, He, Guanghan, Martinez-Rivera, Michelle, Bacha, Jeffrey A., Brown, Dennis M., Siddik, Zahid H.

“…Abstract Cisplatin is an important frontline drug for ovarian carcinoma and non-small cell lung cancer (NSCLC). However, the initial response rates of up to…”
Get full text

Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system by Ning, Shoucheng, Yu, Ning, Brown, Dennis M, Kanekal, Sarathchandra, Knox, Susan J

“…Purpose: Effects of combining local irradiation and intratumoral (i.t.) administration of cisplatin (CDDP) in a sustained-release drug delivery system (epi…”
Get full text

Acute Compartment Syndrome of the Forearm following Autologous Blood Reinfusion: A Case Report by Noyes, Matthew, Coffey, Michael J., Brown, Dennis M., Mesghali, Homayoun

“…Compartment syndrome is a condition with multiple reported etiologies, and permanent disability may ensue if not treated in a timely fashion. We report the…”
Get full text

Kinetics of the reaction between hydrogen and sulfur under high-temperature Claus furnace conditions by Dowling, Norman I, Hyne, James B, Brown, Dennis M

“…The reaction H{sub 2} + (1/2)S{sub 2} {r equilibrium}H{sub 2}S has been studied as a function of temperature and residence time over the ranges…”
Get full text

Neurophysiologic Intraoperative Monitoring During Revision Total Hip Arthroplasty by Brown, Dennis M, McGinnis, William C, Mesghali, Homayoun

Get full text

Abstract P053: VAL-083 (dianhydrogalactitol) synergizes with PARP inhibitors in BRCA-proficient and BRCA-deficient ovarian cancer models by Steino, Anne, He, Guangan, Zhai, Beibei, Bacha, Jeffrey, Brown, Dennis M., Daugaard, Mads, Siddik, Zahid H.

“…Abstract Platinum (Pt)-based chemotherapy plays a key role in ovarian cancer treatment, but patients frequently develop Pt-resistance. Dysfunctional p53 is…”
Get full text

Abstract 1369: Dianhydrogalactitol (VAL-083) synergizes with topoisomerase inhibitors to overcome homologous recombination repair activity in glioblastoma and prostate cancer cells by Zhai, Beibei, Kotapalli, Sudha Sravanti, Bacha, Jeffrey A., Brown, Dennis M., Steino, Anne, Daugaard, Mads

“…Abstract Dianhydrogalactitol (VAL-083) is a bi-functional DNA-damaging agent that targets N7-guanines and causes DNA inter-strand crosslinks. VAL-083 is a…”
Get full text

Abstract NT-109: VAL-083 (DIANHYDROGALACTITOL) SYNERGIZES WITH PARP INHIBITORS IN BRCA-PROFICIENT AND BRCA-DEFICIENT OVARIAN CANCER MODELS by Steino, Anne, He, Guangan, Bacha, Jeffrey, Brown, Dennis M., Siddik, Zahid H.

“…Abstract BACKGROUND: Ovarian cancer is normally treated with platinum (Pt)-based chemotherapy, but patients frequently develop Pt-resistance. Dysfunctional p53…”
Get full text

Abstract 3499: Dianhydrogalactitol (VAL-083) in combination with AZD1775 increases survival in diffuse intrinsic pontine glioma (DIPG), in vivo by Steino, Anne, Yang, Xiaodong, Kline, Cassie, Bacha, Jeffrey, Brown, Dennis M., Mueller, Sabine

“…Abstract OBJECTION: VAL-083 is a structurally unique bi-functional DNA targeting agent that readily crosses the blood-brain barrier and accumulates in brain…”
Get full text

Abstract 1051: Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth upon bevacizumab-induced hypoxia, in vivo by Golebiewska, Anna, Oudin, Anais, Steino, Anne, Niclou, Simone P., Bacha, Jeffrey, Brown, Dennis M.

“…Abstract Background: Standard-of-care for glioblastoma (GBM) includes surgery, radiation and temozolomide (TMZ). Nearly all tumors recur and 5-year survival is…”
Get full text

Abstract A01: Distinct mechanism of action of DNA-damaging agent dianhydrogalactitol (VAL-083) suggests combination therapy with PARP inhibitors by Bacha, Jeffrey A., He, Guangan, Xie, Xiaolei, Steino, Anne, Brown, Dennis M., Siddik, Zahid H.

“…Abstract DNA damage response (DDR) is a network of intracellular pathways designed to minimize the impact of DNA damage. Multiple DNA repair pathways are…”
Get full text

Abstract 1962: Dianhydrogalactitol (VAL-083) has a distinct mechanism of action that suggests combination with PARP inhibitors as an effective therapeutic strategy by Bacha, Jeffrey A., He, Guangan, Steino, Anne, Brown, Dennis M., Siddik, Zahid H.

“…Abstract Ovarian cancer is usually treated with platinum (Pt)-based chemotherapy, but patients frequently develop Pt-resistance. Dysfunctional p53 is…”
Get full text

Abstract 900: Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG by Steino, Anne, Zhai, Beibei, Bacha, Jeffrey A., Brown, Dennis M., Daugaard, Mads, Mueller, Sabine

“…Abstract Despite decades of clinical trials, children with diffuse intrinsic pontine gliomas (DIPG) continue to have a very poor prognosis and dismal survival…”
Get full text

Abstract 5231: Dianhydrogalactitol (VAL-083) exhibits strong efficacy in GBM tumors with different (epi)genetic background and treatment history by Golebiewska, Anna, Oudin, Anaïs, Baus, Virginie, Hau, Ann-Christin, Klein, Eliane, Steino, Anne, Bacha, Jeffrey A., Niclou, Simone P., Brown, Dennis M.

“…Abstract Background: Standard-of-care for glioblastoma (GBM) includes surgery, radiation and temozolomide (TMZ). Nearly all tumors recur and 5-year survival is…”
Get full text

Abstract A109: DNA-damaging agent dianhydrogalactitol (VAL-083) targets HR repair pathway and suggests combination therapy with topoisomerase and PARP inhibitors by Zhai, Beibei, He, Guangan, Steino, Anne, Bacha, Jeffrey A., Brown, Dennis M., Siddik, Zahid, Daugaard, Mads

“…Abstract DNA damage repair (DDR) describes the network of pathways that are responsible for minimizing the effect of daily DNA damage such as mismatched base…”
Get full text

Abstract 2483: Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming chemoresistance in glioblastoma by Zhai, Beibei, Gobielewska, Anna, Steino, Anne, Bacha, Jeffrey A., Brown, Dennis M., Niclou, Simone, Daugaard, Mads

“…Abstract Standard treatments for glioblastoma (GBM) include surgery, radiation and chemotherapy with temozolomide (TMZ). Nearly all tumors recur and 5-year…”
Get full text

Abstract 1429: DNA damage response to dianhydrogalactitol (VAL-083) in p53-deficient non-small cell lung cancer cells by Steino, Anne, He, Guangan, Bacha, Jeffrey A., Brown, Dennis M., Siddik, Zahid

“…Abstract Non-small cell lung cancer (NSCLC) treatment usually involves surgery and chemotherapy with tyrosine kinase inhibitors (TKI) in patients with EGFR…”
Get full text

Abstract CT273: Phase 2 trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated glioblastoma by Chen, Zhong-ping, Guo, Cheng-cheng, Yang, Qun-ying, Lei, Jia-Wei, Wu, Shao-xiong, Johnson, Gregory, Langlands, John, Kwan, Claire, Kanekal, Sarath, Schwartz, Richard, Bacha, Jeffrey A., Steino, Anne, Brown, Dennis M.

“…Abstract Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Current standard-of-care includes surgery followed by chemoirradiation and…”
Get full text

Abstract CT054: Phase II study of dianhydrogalactitol in patients with MGMT -unmethylated bevacizumab-naive recurrent glioblastoma by O'Brien, Barbara J., Bacha, Jeffrey A., Brown, Dennis M., Steino, Anne, Schwartz, Richard, Kanekal, Sarath, Lopez, Lorena, Penas-Prado, Marta

“…Abstract Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Current standard of care includes surgery, radiation and treatment with…”
Get full text

Abstract NTOC-108: ACTIVITY OF DIANHYDROGALACTITOL (VAL–083) IN OVARIAN TUMOR MODELS, SENSITIVE OR RESISTANT TO CISPLATIN by Steino, Anne, Martinez-Rivera, Michelle, He, Guanghan, Xie, Xiaolei, Bacha, Jeffrey A., Brown, Dennis M., Siddik, Zahid H.

“…Abstract PURPOSE: Platinum drug resistance is a major clinical impediment that is normally ascribed to several mechanisms, with dysfunctional p53 playing a…”
Get full text